| Literature DB >> 17496888 |
Anil Koul1, Najoua Dendouga, Karen Vergauwen, Brenda Molenberghs, Luc Vranckx, Rudy Willebrords, Zorica Ristic, Holger Lill, Ismet Dorange, Jerome Guillemont, Dirk Bald, Koen Andries.
Abstract
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17496888 DOI： 10.1038/nchembio884
Source DB: PubMed Journal: Nat Chem Biol ISSN： 1552-4450 Impact factor: 15.040